← All stocks

ARROWHEAD PHARMACEUTICALS, INC.

ARWR Net selling
CIK 0000879407 #848 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$38.04M
$14.00M on a plan · $3.58M straight out of an exercise
Sold at will
$20.46M
20 of 65 sales
Net
−$38.04M
−$20.46M against sales at will

By person

14 insiders · 65 transactions
337×

Christopher Anzalone holds 337 times base salary in stock. $331.11M of shares against $981.05K in salary for 2025.

Salary from the company's own proxy. The shares are what Christopher Anzalone last reported holding, valued at $87.30, the price Common Stock was last bought or sold at on the open market here, on 18 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Anzalone Christopher Richard
Chief Executive Officer
$24.01M (25)
−$24.01M
3,792,739
2.69%
$331.11M
+2.1%
Hamilton James C
Chief Medical Officer
$4.63M (10) scheduled
−$4.63M
226,958
0.1607%
$19.81M
+10.8%
O'Brien Patrick
COO
$3.12M (12) scheduled
−$3.12M
547,408
0.3875%
$47.79M
+17.9%
PERRY MICHAEL S
Director
$2.00M (2)
−$2.00M
111,459
0.0789%
$9.73M
−2.9%
Ferrari Mauro
Director
$1.02M (2) scheduled
−$1.02M
69,053
0.0489%
$6.03M
+13.6%
Apel Daniel Joseph
Chief Financial Officer
$934.29K (3) scheduled
−$934.29K
162,905
0.1153%
$14.22M
+61.3%
OLUKOTUN ADEOYE Y
Director
$850.54K (4) scheduled
−$850.54K
31,600
0.0224%
$2.76M
+38.3%
Vakiener Victoria
Director
$679.49K (3) scheduled
−$679.49K
35,723
0.0253%
$3.12M
+18.3%
Waddill William D.
Director
$566.04K (3) scheduled
−$566.04K
56,563
0.0400%
$4.94M
+18.2%
Lu Hongbo
Director
$228.33K (1) scheduled
−$228.33K
52,012
0.0368%
$4.54M
+70.9%
Myszkowski Kenneth Allen
Chief Financial Officer
455,433
0.3224%
$39.76M
+13.7%
GIVEN DOUGLAS B
Director
124,167
0.0879%
$10.84M
−4.3%
INGRAM DOUGLAS S
Director
46,215
0.0327%
$4.03M
Cohen Matthew Gregory
Director
11,882
0.0084%
$1.04M

Nothing of that kind in this period.

What was left out

Form 4 filings counted 31
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 43
Sales straight out of an exercise 2
Sales at will 20
Transactions with no price 0
Shares from compensation/vesting 528,641
History held since 18 Oct 2016